BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Kerecis to Present at Seed Forums in London and New York


11/4/2010 9:17:46 AM

REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND--(Marketwire - November 03, 2010) -

Kerecis ehf, the emerging tissue-regeneration company, today announced that its Chairman G. Fertram Sigurjonsson will make presentations at seed forums this week and next.

The first, the London Seed Forum, takes place at the European Bank for Reconstruction and Development on Thursday, November 4. The second takes place in New York on Tuesday, November 9.

Kerecis, which recently raised $700,000 from Iceland's New Business Venture Fund, is looking to close further financing by the first quarter of 2011. The money will be used to complete regulatory registration and complete the ongoing clinical trial of the company's product, the Marigen Lipid Enhanced Matrix.

This patent-pending, marine-derived, tissue-regeneration product has applications across multiple medical-device sectors including wound care and abdominal wall reconstruction.

Statistics show a large need for wound care. Each year about 6 million Americans suffer from problem wounds caused by diabetes, circulatory problems and other conditions, with 1.1 to 1.8 million new cases added each year.

More than 20 million Americans have diabetes; almost 20 percent of them are over the age of 60. Fully 15 percent of all diabetics develop problem wounds, and more than 100,000 diabetics undergo amputation each year because of such wounds in the United States alone.

Also, more than 1 million hernia repair operations are performed annually in the U.S. A staggering 10 to 25 percent of these patients have postoperative pain and discomfort, and a substantial number of patients have to be re-admitted.

According to Sigurjonsson, Marigen offers significant advantages over existing human-and porcine (pig)-derived products, including lower risk of disease transfer, better manufacturing economics, and the absence of religious and cultural constraints on usage. The product is easier to use than most competing biologic products because it is softer and more conformable, and because it comes in larger, thicker sheets, eliminating the need for multi-layer grafts. For hernia repair the Marigen technology offers better durability and cell-integration capability than other products on the market.

Comments
G. Fertram Sigurjonsson, Kerecis Co-Founder and Chairman of the Board:

"The effective treatment of chronic, non-healing wounds is a major unmet need in modern health care. Preliminary results from our clinical trials are very encouraging and we expect to have regulatory approval for our products on major markets like the U.S. within a few months. At the seed forums we will be updating the investor community about our progress to encourage additional investor and potential partner interest in our programs."

About Kerecis
Kerecis (http://www.kerecis.com) is a development and manufacturing business producing a novel, patent-pending tissue-regeneration material derived from fish skin to accelerate the healing of wounds and tissue reconstruction. Kerecis' material addresses the large unmet need of the double-digit growth biologics segment of the chronic-wounds and hernia-repair markets. The material offers advantages over existing human- and porcine-derived products, including improved manufacturing economics and lower risk of disease transfer. Since it is derived from fish, the material is both kosher and halal compatible, eliminating cultural and religious constraints on usage, with equivalent or better clinical performance. For more information, e-mail info@kerecis.com or call 703-879-6535 (U.S.) or 354-8494960 (Iceland).


For further information, contact:
G. Fertram Sigurjonsson
Chairman, Kerecis ehf.
Phone (Iceland) +354 8494960
(U.S.) (703) 879-6535
E-mail: Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

Kerecis
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES